Intelerad workflow solution to include Zebra Medical Vision’s AI offerings

Intelerad Medical Systems and Zebra Medical Vision have announced a new partnership involving Intelerad’s Odyssey workflow management solution.

As a part of this arrangement, Zebra-Med’s bundle of AI solutions, AI1, will now be included as a primary building block of Odyssey. The move, according to a prepared statement from both companies, is “designed to encourage the adoption of artificial intelligence without the prohibitive costs usually associated with such programs.”

Odyssey also charges users per study, a feature put in place to keep costs down for providers who may not want to pay a flat fee right off the bat. A 12-month trial is also being offered to celebrate the release of Odyssey, an offer only available “for a limited time.”

“Odyssey will deliver state-of-the-art clinical AI solutions directly integrated into the radiologists’ natural workflow and tailored to the needs of individual organizations,” Chris Wood, chief technology officer at Intelerad, said in the prepared statement. “With Zebra-Med’s AI1, we are committed to providing a broad and growing portfolio of high-value, innovative technology solutions to our customers and this unprecedented approach to artificial intelligence in radiology will extend our leadership position in workflow management.”

“We are excited to be supporting Intelerad’s team and the 300 healthcare organizations they serve, with our ‘all-in-one’ AI1 ever-growing portfolio of FDA-cleared AI products,“ Eyal Gura, CEO of Zebra Medical Vision, said in the same statement. “We are committed to bring more AI value in an integrated way to the workflow and in all modalities.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup